Abstract
Molecular-targeted drugs, especially angiogenesis inhibitors, have improved outcomes in a variety of solid cancers in the metastatic, but not adjuvant, setting. Although various mechanisms have been proposed [1], the true reasons for this discrepancy between metastatic and adjuvant settings are not known. Renal cell cancer (RCC) is a highly vascular tumor and angiogenesis inhibitors such as sorafenib, sunitinib, pazopanib and axitinib have already shown clinical benefit in the metastatic setting. However, the efficacy of these agents in the adjuvant setting was until recently unknown. Two recently published phase 3 randomized controlled trials (RCTs)—the ASSURE trial [2] and the S-TRAC trial [3]—have tested sunitinib as an adjuvant treatment for high risk, resected RCC with discrepant results. Hence, we performed a meta-analysis to evaluate the benefit and risks of adjuvant treatment with sunitinib in this setting.